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Preface 
Cancer cells are endowed with diverse biological capabilities driven by myriad inherited 
and somatic genetic and epigenetic aberrations that commandeer key cancer-relevant 
pathways.  Efforts to elucidate these aberrations began with Boveri’s hypothesis of aberrant 
mitoses causing cancer and continue today with a suite of powerful high-resolution technologies 
that enable detailed catalogues of genomic aberrations and epigenomic modifications.  
Tomorrow will likely bring the complete atlas of reversible and irreversible alteration in individual 
cancers. The challenge now is to discern causal molecular abnormalities from genomic and 
epigenomic “noise”, to understand how the ensemble of these aberrations collaborate to drive 
cancer pathophysiology.   Here, we highlight lessons learned from now classical examples of 
successful translation of genomic discoveries into clinical practice, lessons that may be used to 
guide and accelerate translation of emerging genomic insights into practical clinical endpoints 
that can impact on practice of cancer medicine. 
 
 
Introduction 
The human cancer genome harbors wholesale alterations on the chromatin, 
chromosome and nucleotide levels, resulting in irreversible numerical and structural aberrations 
as well as reversible epigenetic modifications (Figure 1) that affect hundreds to thousands of 
genes or regulatory transcripts.  Collectively, these molecular abnormalities serve to activate or 
neutralize biological events that define diverse aspects of cancer pathophysiology including 
altered growth, death, metabolism, angiogenesis, immune sequestration and metastasis 1.  
Mining the complex cancer (epi)genome for aberrations governing these processes has become 
a major activity in cancer research, as it is widely appreciated that embedded within the 
oncogenomic landscape are mechanistic clues to disease pathogenesis that can inform the 
broader efforts of identifying molecular events for therapeutic intervention and molecular 
biomarkers for early detection and prognosis, improved diagnosis and response prediction.  
Recognizing this, multiple national and international efforts, including The Cancer Genome Atlas 
(TCGA) pilot project by the NCI and NHGRI 2, have been initiated to accelerate the compilation 
of the comprehensive atlas of cancer genomic alterations.  
In recent years, cancer genomics – defined here as the study of the ensemble of DNA-
associated abnormalities that enable and accompany cancer development - has exploded as a 
field, enabled by genome-wide high-resolution high-throughput platforms (see textbox). These 
technologies now yield informative but dauntingly complex multi-dimensional genomic datasets 
that describe in detail the myriad changes in epigenomic modifications and DNA copy number 
and structural aberrations as well as sequence mutations within individual tumors and how 
these differ between individual tumors.  There is real potential that these datasets will transform 
the practice of cancer medicine as evidenced by therapies that target distinctive molecular 
events that result from genome aberrations features such as EGFR mutations (gefitinib or 
erlotinib)3-5, the BCR-ABL translocation (imatinib mesylate)6 and ERBB2 amplification 
(trastuzumab, lapatinib) 7 and assays for these aberrations that are now used to stratify patients 
for treatment.  In parallel, assays for germline mutations identify individuals at high risk of 
cancer development – for example, p53 mutations are associated the Li-Fraumeni cancer 
syndrome8, BRCA1/2 mutations signal increased risk for breast and ovarian cancer risk9-11, 
mutations or epigenomic modification of DNA mismatch repair (MMR) genes such as MLH1 or 
MSH2 or MSH6 associates with hereditary non-polyposis colorectal cancer (HNPCC)12 and 
CDKN2A mutations indicate increased risk for familial atypical multiple mole melanoma-
pancreatic cancer 13.   
 These examples have demonstrated the promise of cancer genomics, stimulated rapid 
advances in genome technologies and computational science, and galvanized an entire 
generation of multi-disciplinary scientists on the quest to identify the next set of key cancer 
targets and disease biomarkers.  While there has been tremendous success in the rapid 
accumulation of genomic data, vast majority of these enormous datasets have not yet translated 
into meaningful clinical endpoints. Historically, translation of each genome aberration 
discoveries into improved patient management has taken at least a decade and sometimes 
billions of dollars. This pace and expense will not permit the range of genomic discoveries to be 
effectively exploited unless more efficient, less costly strategies are developed.  What are the 
barriers to rapid conversion of genomic information into useful diagnostics and effective 
therapeutics?  Is statistical significance in the absence of mechanistic insights sufficient to 
harness the full translational potential of these complex genomic datasets in a cost-efficient and 
effective way?  Or, is some degree of molecular biological function required for efficient 
translation?  In this regard, the ABL, ERBB2 and EGFR paradigms appear to support the view 
that the coupling of genomic insights with pathobiology holds the greatest promise for clinical 
impact.  In this article, we will review some examples of successful translation of genomic 
discoveries to the clinic and lessons learned from these first experiences.  Against this 
backdrop, we will discuss the challenges and potential paths forward to translate the promise of 
a complete cancer genome atlas.  
 
Historical lessons 
There have been several pioneering examples of successful translation of genomic 
aberration discoveries in cancers into diagnostics and therapeutics with dramatic impact on 
practice of cancer medicine.   Although many of these successes predated present-day high-
throughput genome-wide technologies – indeed, some resulted from decades of painstaking 
work - they nevertheless presage the translation of cancer genomic discoveries into useful 
clinical tests and effective treatments.  We review several here as lessons for modern genome 
researchers that may guide and accelerate translation of the genome aberrations now being 
discovered.  
Translocations.  The first recurrent genome aberration discovered to be associated with 
a human malignancy was the “Philadelphia chromosome” discovered by Nowell and Hungerford 
in 196014.  In the ensuring decades, cytogenetic and molecular studies showed this to be a 
translocation between chromosomes 9 and 22, resulting in a fusion product, BCR-ABL.  This 
fusion gene deregulates tyrosine kinase activity in patients with chronic myeloid leukemia (CML) 
and some forms of acute lymphoblastic leukemia (ALL).  More than 30 years after the discovery 
of the Philadelphia chromosome, a kinase inhibitor, imatinib mesylate, was developed as an 
effective therapeutic agent against BCR-ABL in patients with CML6.  Unfortunately, despite 
initial dramatic responses, this targeted therapy does not lead to durable cure since resistant 
tumors emerge that abrogate the inhibitory effect of imatinib mesylate15. Genomic analyses of 
the resistant tumors showed the acquisition of point mutations (sometimes amplified). This 
insight guided development of new kinase inhibitors designed to counter this resistance 
mechanism, leading to recent approval of nilotinib and dasatinib16.  This suggests a recursive 
paradigm of therapy/biomarker developments in which genomic analysis guides the 
development of targeted therapies and associated predictive markers followed by genomic 
studies of resistant tumors to aid development of second and third generation inhibitors to 
counter resistance mechanisms.  Banking of tumor tissues from drug resistant patients will be 
essential to support these studies.  Another lesson to be learned from the imatinib mesylate 
story is that genomic analyses can effectively guide the use of small molecule inhibitors that 
show multi-target specificity.  Imatinib mesylate, for example, also inhibits the c-Kit receptor 
tyrosine kinase.   Guided by genomic analyses of gastrointestinal stromal tumors (GIST 
sarcomas)17 and mucosal melanomas18 showing that both harbor c-Kit mutations,  imatinib has 
been successfully used to treat patients with GIST (sarcoma) and mucosal melanomas17-19.    
Numerous causal recurrent translocations have been discovered in human leukemias 
and lymphomas via molecular cytogenetic analyses since the pioneering discovery of the 
Philadelphia chromosome20.  However, discovery of causal translocations in solid tumors has 
been difficult, possibly reflecting the complex genomic profiles and heterogeneous nature of 
these malignancies.  With current day genomic analyses coupled with sophisticated analytical 
approaches and expanding genomic information, recurrent structural aberrations are being 
discovered in solid tumors and may be more prevalent that previously thought.  A notable 
discovery is the high-frequency of TMPRSS2:ETS-family translocations in human prostate 
cancer.  Using a novel integrative analytical methodology called COPA (Cancer Outlier Profile 
Analysis) that identifies associations between genomic and transcriptional abnormalities, 
Chinnaiyan and colleagues identified this family of common translocations that brings an 
oncogenic ETS transcription factor under control of the androgen response element TMPRSS2, 
effectively placing expression of the ETS oncogene under androgen regulation21. Molecular 
assays for the fusion events are now being developed and evaluated as early detection markers 
for prostate cancers22. Similar computational approaches on emerging multi-dimensional 
datasets will hopefully yield other causal structural aberrations in solid tumors.  And this is only 
the beginning.  Next generation sequencing technologies that enable DNA sequence analysis of 
entire tumor genomes will be particularly valuable in discovering fusion genes and other 
structural rearrangements.  The promise of this approach is illustrated by the revelation of 
remarkable structural complexity in the cancer genomes by end sequence profiling23 or genomic 
region sequencing24. 
Gene amplification.  Another prominent success story involves the now well-established 
oncogene, ERBB2.  This gene with homology to erb-B and the tumour antigen p185 was initially 
identified as a transforming oncogene in NIH-3T3 cells25 that was also amplified in human 
breast cancer cell lines26-28.  Shortly thereafter, ERBB2 amplification was found in ~30% of 
primary tumors wherein amplification was associated with short survival duration and time to 
relapse29.  Based on these observations, diagnostic assays for Her2 amplification30 or 
overexpression were developed and used in early clinical trials of trastuzumab (a monoclonal 
antibody directed against the extracellular domain of HER2) to demonstrate survival benefit in 
Her2 positive metastatic breast cancer patients7.  More recently, molecular assays for ERBB2 
have guided the clinical deployment of the EGFR/ERBB2 targeted small molecule inhibitor, 
lapatinib 31.   
Mutations.  Since completion of the human genome sequence, several high-impact 
discoveries in genome science have come from systematic re-sequencing of cancer genes or 
pathways or gene family.  One of the first and perhaps the most celebrated success from such 
large-scale sequencing projects is the discovery of frequent activating somatic mutations in 
BRAF, a serine threonine kinase in 60% of malignant melanoma, 10% of colorectal cancer as 
well as in lower frequencies of other cancers32.  This discovery has driven multiple BRAF 
inhibitor development programs with several drugs already entered clinical trials.   Other notable 
discoveries from large-scale sequencing efforts included frequent PI3KCA33 and AKT134 
mutations in many cancer types, ERRB2 and EGFR mutations in NSCLC35,36, among others.  
The discovery that, in addition to gender, ethnicity, smoking history and histopathological 
subtypes; EGFR-activating mutations predict responses to anti-EGFR targeted therapies in 
chemotherapy-refractory advanced NSCLC patient 3-5 has immediately changed the standard of 
care for patients with NSCLC.  EGFR mutation testing is becoming routine prior to treatment 
decision with EGFR inhibitors36.  Here, the ability to assay EGFR genotype retrospectively using 
banked tumor tissues with matched germline DNA was crucial in enabling the stratification of 
responders and demonstration of efficacy, leading ultimately to FDA approval of erlotinib for 
NSCLC37.  A lesson to learn from this is the importance and values of uniform collection of pre- 
and post-treatment tumor specimens with matched normal controls from clinical trials to enable 
future prospectively designed retrospective analyses of clinical responses, perhaps even at the 
expense of slower patients accrual.    
Germline susceptibility. In addition to somatic genetics, genomic science is also 
revolutionizing our searches for germline susceptibility genes or polymorphisms in inherited 
disease predisposition including cancers.  One of the early successes in this area was the 
discovery of BRCA1 mutation association with familial breast cancer9,10. Genetic screening for 
germline mutations in BRCA1 and now a second cancer susceptibility gene, BRCA211 are now 
being deployed world-wide to identify patients at high risk of developing early onset breast and 
ovarian cancer.  Moreover, the knowledge that BRCA1 is necessary for error-free double-strand 
break repair led the way to development of PARP inhibitors, a new treatment paradigm38.  
These and subsequent studies established the concept that efforts to discover inactivating 
germline mutations associated with increased susceptibility to cancer can be guided by 
analyses of LOH or reduced genome copy number and/or methylation in the tumors that 
eventually develop.  Application of current and future day genomic technologies in coordinated 
germline and tumor studies are likely to significantly accelerate that identification of 
susceptibility genes of this class thereby enhancing our ability to stratify high-risk individuals for 
aggressive surveillance, prevention and management.  However, this will require coordinated 
collection of tumor specimens along with germline DNA in large cohort genetic susceptibility 
studies. 
 
Making sense of the oncogenome  
Empowered by our improved capability to survey the cancer genome with increasing 
accuracy and resolution, hundreds of cancer genomic studies have been conducted or initiated 
with the hope of discovering the next EGFR, HER2 or BRAF.  Instead, these analyses are 
uncovering hundreds of recurrent genomic or genetic alterations impacting thousands of 
“genetic elements of interest (GEOI)” – including annotated genes, non-coding micoRNA, or 
other conserved elements – that might contribute to the pathophysiology of human cancers.  
The nature and “strength” of each GEOI, our certainty of its contribution and therefore its 
translational importance varies substantially.  Some will be strong, causal “drivers” of important 
cancer hallmarks1, others will be weaker but important “contributors” to the development of 
cancer pathophysiology while many will be genomic “noise” or “passengers” that are biologically 
neutral and have been accumulated by chance during the cancer’s life history.   Distinguishing 
the drivers and contributors from the passengers is a central challenge in genomic research 
today.  This is made more challenging by the diversity of GEOI function and the likelihood that 
GEOI function may be tumor type (or subtype) as well as microenvironment dependent.   
In cases of high-frequency events such as amplifications of regions encoding EGFR in 
GBM (45%) or ERBB2 in breast cancer (20%); deletions of regions encoding CDKN2A or PTEN 
in upwards of 80% in solid tumors or mutations of p53, RAS, BRAF and PIK3CA in a wide range 
of solid tumors (see http://www.sanger.ac.uk/genetics/CGP/Census/), assignment of GEOIs as 
“drivers” is compelling and rests on weight of functional evidence built up over decades, a 
“luxury” not afforded by novel GEOIs born to present day high-throughput cancer genomics.   
Furthermore, these prominent “gene-mountains” appear to be few and far between relative to 
the numerous “hills and valleys” stretching broadly over large regions of the oncogenome 39,40.  
Which of these GEIOs are on the critical path to malignancy?  What are their relative 
contributions?  These are challenging questions without simple answers, but they do converge 
on the theme of integration and triangulation (Figure 2).  Below we highlight several examples of 
approaches that have been utilized successfully to find the “needles” – drivers and contributors 
– in the haystack of cancer genome data.  
 
Integrative analyses of multi-dimensional data 
The cancer genome is dysregulated by multiple mechanisms, including DNA and 
chromatin modifications and changes in DNA structure, copy number and mutations of coding 
and non-coding sequences that alter RNA transcription, translation, gene function and/or post-
translational modification.  Technological advances that allow examination of the cancer 
genome in multiple “omic” dimensions are helping to focus driver and contributor discovery 
since these GEOIs tend to be deregulated by several different mechanisms.  A classic example 
is the CDKN2A (p16INK4A/p14ARF) tumor suppressor, which can be inactivated by homozygous 
deletion of the 9p21 locus, epigenetic silencing of gene expression via promoter methylation, or 
point mutations crippling p16INK4A functions41.  Similarly, the oncogene, PIK3CA, can be 
activated by amplification and over-expression42 and/or activating mutations33.   Such multi-
mechanism deregulation is clearly illustrated when examining well-known bona fide oncogenes 
in a typical signaling pathway (Figure 3).  In other words, if it is important, cancer will find a way 
to deregulate a genetic element by any mechanism possible.  By this reasoning, targeted re-
sequencing of resident genes within regions of amplification has yielded clinical fruits, such as 
KIT in mucosal and acral melanomas18.  Thus, demonstration of complementary modes of 
deregulation through integration of multiple dimensions of genomic information is a piece of 
strong evidence in support of a likely pathogenetic GEOI.  The current large-scale cancer 
genome projects with coordinated comprehensive genome-wide characterization will be most 
powerful in leveraging such multi-dimensional data for integrative analyses.  Additionally, 
triangulation across tumor types can be highly informative as well, as it is clear that the 
mechanisms of deregulation of many bona fide cancer genes, such as MYC, EGFR, AKT, RAS 
or p53, PTEN and CDKN2A vary according to tumor type – for example, genes like MYC that 
are activated by translocation in leukemias may be activated by amplification in solid tumors.  
Convergence among different tumor types can rapidly prioritize GEOIs that are likely to be 
important broadly.  As a byproduct, it is likely that the predictive or prognostic power of genome 
biomarkers will increase substantially if assays are developed that assess the accumulated 
effect of all mechanisms of deregulation, such as changes in protein level or structure. 
 
Comparative oncogenomics  
Evolutionary conservation can be a powerful guide to cancer gene discovery since 
genes involved in pathways that are deregulated in cancers such as  RTK signaling, cell cycle 
regulation and apoptosis are strongly conserved across species43,44.  This comparative 
approach proved to be enormously helpful in refining the draft of the human genome.  With 
respect to cancer, it has been established that cancer genes from one species can effect the 
malignant transformation of cells derived from different species despite poor primary sequence 
conservation (e.g., dMyc transformation of rodent cells 45).  Recent large-scale cross-species 
comparison has established that mouse and human tumors sustain orthologous genomic events 
which target novel cancer genes in diverse tumor types 46-48, supporting the view that genomic 
alterations conserved across species are more likely to represent critical events in 
tumorigenesis, and that evolutionary conservation can provide a potentially powerful solution to 
the central problem of noise in genomic datasets.  
While it began with histopathological diagnoses, cross-species comparison has evolved 
to include genetic/genomic analyses to demonstrate that genetically engineered mouse models 
can model genetic aspects of human cancer, as exemplified by cross-species conservation of 
transcriptional signatures for KRAS activation in lung cancers49 or somatic mutations of 
NOTCH1 in mouse and human T cell leukemia 50.   This was followed by proof-of-concept that 
comparison of genomic profiles of mouse and human tumors enabled discovery of novel 
oncogenes46,47.  In the case of the study by Kim et al, ability to manipulate stages of tumor 
evolution, from regression to recurrence to escape in vivo, was leveraged to force selection of 
aberrations conferring metastatic capability.  Genome-wide copy number profiles revealed focal 
amplification in mouse metastastic tumors that were syntenic to human 6p24-25, a region that 
sustains copy number gain in 36% of human metastatic, but not primary, melanoma51.  Although 
6p gain is highly recurrent, suggestive of potential pathogenetic and/or prognostic importance in 
human tumors, its extended nature in human tumors renders identification of 
drivers/contributors difficult to impossible.  Given the focal nature of the event in the mouse, 
cross-species comparison was able to narrow one region of interest to an 850 KB region 
encompassing only 8 annotated genes, with NEDD9 as a putative driver. With that information 
as a guide, further functional and clinicopathological studies documented NEDD9s metastasis-
promoting activities, and elucidated its molecular action via focal adhesion kinase46.   Likewise, 
comparisons of recurrent genome copy number aberrations in tumors with ERBB2 amplification 
in human breast tumors and in a transgenic mouse model in which oncogenic Erbb2 (NeuNT) 
was expressed under control of the endogenous Erbb2 promoter implicated GRB7 and 14-3-3-σ 
as contributors in ERBB2 mediated oncogenic process52.   
While syntenic aberrations have been observed between murine and human tumors, it is 
important to note that genomes of most mouse tumors accumulate far fewer genome 
aberrations than do human solid tumors.  For example, mouse tumors from oncogene-driven 
mouse models often exhibit few to no copy number aberrations (CNAs), and infrequent (typically 
simple) CNAs presumably occur only under strong selective pressure.  This simplicity facilitates  
genomic identification driver and contributor aberrations as exemplified by studies by Kim et al 
and Zender et al 46,47.  On the other hand, the disadvantage is that it does not lend itself to 
widespread use of cross-species comparison.   
Based on the observations that telomere dysfunction-induced DNA breakage events can 
drive regional amplifications and deletions and that laboratory mouse does not experience 
telomere-based crisis, DePinho and colleagues knocked out in the mouse germline the RNA 
component of the telomerase holoenzyme, generating a telomerase-deficient mouse that 
experienced progressive shortening of telomere length through successive generations, 
eventually leading to crisis53.  Tumors from these animals indeed showed high level of 
instability, harboring large number of non-reciprocal translocations and complex CNAs 54-56.  
Unbiased genome-wide comparison of such genome-unstable murine tumors and several 
human cancers of diverse origins demonstrated compelling non-random overlaps over copy 
number aberrations, proving that murine and human tumors experience common biological 
processes driven by the orthologous genetic events 48.  Attesting to the potential of such cross-
species comparison for gene discovery, focused re-sequencing of GEOI within syntenic 
deletions revealed high frequency mutation of FBXW7 in human T-ALL, and PTEN48, the latter 
also shown to modify responses to NOTCH1 inhibition in clinic57.  These studies support the 
notion that cross-species synteny serves not only as a measure of validation by virtue of their 
evolutionary conservation and utilization of different genetic mechanisms (i.e., mutation and 
copy number), but also guide the discrimination of drivers/contributors from bystanders.  
Another aspect where the mouse has proven its value in comparative genomics is in 
identification of susceptibility loci.  Extending the concepts used to identify BRCA1, one might 
expect to find mutations or polymorphisms that contribute to cancer susceptibility be subjected 
to positive selection during cancer genome evolution.  Thus, these mutations might be found 
through allele specific analysis of genome copy number and gene expression in defined model 
systems.  As an example, Balmain and colleagues used genomic strategies to identify 
polymorphic variants of the aurora kinase, AURK or STK15, to be associated with increased risk 
of developing cancer in multiple anatomic sites in the mouse58,59.  These studies began with 
analysis of the genetic localization of quantitative trait loci (QTL) in mice that controlled 
susceptibility to skin tumor formation in interspecific mouse crosses (Mus musculus x Mus 
spretus).  One of these, Skts13, was orthologous to a region of recurrent copy number increase 
in human cancers of the breast, colon, ovary and colon at 20q13 that encoded the aurora 
kinase, AURKA.  Analyses of expression of the mouse ortholog, stk6, showed allele specific 
difference in the mouse intercrosses while genome copy number analyses of AURKA 91A and 
AURKA 91T showed preferentially amplification of the AURKA 91A allele in human colon 
tumors.  A subsequent meta analysis of the association of AURKA T+91A alleles risk of cancer 
development of the colon, breast, prostate, skin, lung and esophagus showed an increased risk 
in both homozygotes and heterozygotes. These results confirmed that the AURKA T+91A 
variant is a low penetrance cancer susceptibility allele affecting multiple cancer types.  Overall, 
this integrative analysis of quantitative cancer traits in mice, analysis of allele specific copy 
number change and expression and assessments of susceptibility in large case control studies 
may be essential to identify the likely large number of low penetrance, high prevalence 
polymorphisms that influence cancer risk. 
Finally, model systems including the mouse are ideally suited for forward genetic 
screens where one can “listen” and let the cancer cells “tell” us what events they require or 
prefer on their path toward full malignant transformation.  For example, retroviral insertional 
mutagenesis in the mouse has yielded recurrent and common insertion sites at genomic loci 
encoding genes such as RAS, Myc, Notch1, Flt3, Kit or p53 (60 and references therein), 
attesting to their potential power as cancer gene identification when triangulated with existing 
and emerging human cancer genomic data.   
 
Cell line model systems 
Much of our understanding of cancer cell biology including aspects of gene regulation 
and signaling has come from studies of cancer cells in culture.  The roughly 50,000 publications 
describing uses of the HeLa cell line and 20,000 publications describing uses of the NIH 3T3 
cell line attest to this fact.  That said, no cancer biologist or geneticist will argue that established 
tumor cell lines grown on plastic dishes, in thee dimensional cultures or in immune 
compromised mice can fully recapitulate all biological aspects of human tumors growing in the 
complex human microenvironment.  Nor can any models fully represent the responses of the 
range of human tumors to therapy – in part due to differences in biological environment and in 
part because the models do not capture the range of biological and (epi)genomic diversity found 
in human tumors.  Therefore, it is expected that each model system has pros and cons, strength 
and weakness.  Mouse is one such example; as highlighted above and discussed in greater 
details elsewhere 61, its value is unequivocal.  As long as we are mindful of the limitations of any 
one model, we can leverage information such system can offer.  Integrating across multiple 
models will bring us closer to a true picture.   
So, what CAN we learn about genomic aberrations from cell line models?  And why are 
they important?  Simply put, cell lines are essential for functional and biological validation of 
GEOI.  Almost without exception, demonstration of functional activities and molecular bases for 
their action are necessary for the discovery of novel cancer genetic elements, including genes 
or microRNAs.  Such efforts inevitably begin with various cell model systems, including 
established cancer cells, for their ease of manipulation and versatility (Figure 4).  In such 
system, one can simulate the cancer-associated events (e.g. enforced expression of a GEOI 
resident in an amplification or RNAi-knockdown of a GEOI in a deleted region) to interrogate the 
biological and biochemical consequences of GEOI deregulation and to define its role (e.g. driver 
vs contributor vs passenger) in cancer development.  Clearly, a major obstacle to accurate 
interpretation of functional data in established cancer cell lines is the lack of clarity on the 
complements of genetic alterations they carry, as it has become clear that genotypes of the 
system, be it a cell line, a model or even a patient, can dictate behavior of the cancer cells and 
alter response to a manipulation such as RNAi knockdown or pharmacological inhibition. As in 
the case of the tumors from which they were derived, no two cancer cell lines are alike. 
Moreover, there is the legitimate concern that genomic aberrations will be gained or lost during 
extended passages in culture. Therefore, it is important that cell line models – on plastic, in 3-
diminesional culture or in xenografts - are subjected to same level of comprehensive genomic 
characterization as human tumor specimens so that interpretation of functional studies can be 
guided by knowledge of the similarities and differences between the cell lines and tumors they 
are intended to model.  It is also important that any cell line “system” used for functional 
oncogenomic studies is comprised of multiple independent cell lines with molecular diversity.  If 
sufficiently diverse, analyses of such cell line collections minimize the risk that the elucidated 
function of an aberration will be idiosyncratic to a particular cell line.    
As in model organisms, forward functional genetic screen using cancer cell line model, 
particularly in recent years with advance of RNAi technology, has been touted as one powerful 
platform to identify cancer relevant genes.  Such screens in vitro may be limited by the 
phenotype (life and death, predominantly) amenable to high-throughput biological assays.  
Nonetheless, recent studies that intersect high-throughput RNAi screen in vitro with human 
cancer genomic data have led to the identification of REST as a tumor suppressor in colon 
cancer 62, IKBKE as an oncogene in breast cancers 41 and PIK3CA mutations as important 
determinants of resistance to trastuzumab 63.   
Cell lines also represent an important model system for drug sensitivity and resistance in 
the quest to identify possible biomarkers to guide early phase clinical trial studies, to identify 
drugs that may be effective in tumor subtypes that are resistant to the current standard of care 
and to identify effective drug combinations. Although still in its infancy, a growing literature 
supports the concept that analyses of responses of collections of molecularly characterized cell 
lines to chemotherapeutic agents targeting molecular mechanisms intrinsic to the tumor cells 
will reveal molecular markers that can be used to predict drug response64 65-68.  As a corollary, 
these analyses also identify drugs with high specificity to cancer cell subsets defined by specific 
molecular characteristics. Examples include in vitro analyses that predict (a) the known 
sensitivities of ERBB2 amplified tumors to trastuzumab 69 and lapatinib 66, (b) the sensitivity of 
tumors carrying EGFR mutations to gefitinib3-5, and (c) acquired gefitnib resistant mutation in 
EGFR 70 as well as (d) the resistance of tumors with mutated or amplified BCR-ABL to imatinib 
mesylate 71.   
In short, while not fully recapitulating real tumors in patients, cell model systems with 
large number of independent established lines of broad molecular and cellular diversity 
accompanied by comprehensive genomic characterization can be and will be tremendously 
useful in translation of genomic insights to clinical endpoint.  These systems can be further 
improved by development of (i) co-culture or 3D culture conditions that better model in vivo 
microenvironment and (ii) strategies to establish primary or short-term cultures that minimize 
“culture-shock” associated with adaptation to plastics. 
 
Molecular understanding in translation 
Through integrative analyses of multi-dimensional data and comparison across multiple 
model systems or species (Figure 2), the process of identifying driver/contributor GEOIs, 
especially the relatively weaker or less prevalent ones (e.g. the hills and valleys) can be greatly 
accelerated.  But is this milestone of ‘guilt by association’ sufficient for translation?  We think 
not.  Cancer is a complex and heterogeneous collection of disease entities as defined by 
clinical, histopathological and genetic parameters.  Given this disease heterogeneity, the 
identification of compelling correlation defined in a test-validation set in a laboratory setting (e.g. 
a collection of genomic data; behavior in a model system, even responses in a clinical trial), no 
matter how significant, may not apply generally (i.e., the next new patient entering hospital care 
or enlisted into a randomized Phase III clinical trial).  We believe that, without a definition of the 
genomic and biological context under which these GEOIs exert their mission-critical roles in 
cancer (i.e., its neutralization is associated with a robust anti-oncological response), the full 
therapeutic, diagnostic, and/or prognostic value of these genomic insights will not be realized 
but rather will be lost in translation. 
Consider the example of EGFR mutations in NSCLC and GBM.  Mutational activation of 
EGFR in NSCLC identifies a subpopulation of patients highly responsive to targeted inhibition of 
EGFR.  The percentage of patients with EGFR activation mutation in NSCLC is small (circa 
10% in US studies, somewhat higher in Asian populations) 36, and thus the therapeutic 
response of these patients to gefitnib would not have emerged in the absence of genetic 
stratification of this clinically distinct population. Conversely, EGFRvIII deletion and amplification 
are very prevalent in GBM (approximately 45%) 72, yet EGFR TKIs show a strikingly meager 
clinical impact.  A positive, albeit transient, clinical response has been detected in patient 
subsets with an EGFR event and intact PTEN 73, indicating this key downstream molecule can 
modify the tumor biological response.  However, it is notable that these positive responses are 
not durable despite documented pharmacological extinction of mutationally activated and 
amplified target.  Here, the proteomic profiling of RTK activation patterns in solid tumors, 
including GBM and lung cancer, has provided a rational explanation for the patterns of clinical 
responses.  Specifically, Stommel et al showed that established GBM tumor cell lines, 
xenotransplants and primary patient specimens possess multiple co-activated RTKs, and that 
inhibition of EGFR alone can lead to replacement by other co-activated RTKs in the PI3K 
complex, thus maintaining downstream survival signaling74.  Downstream signaling was 
extinguished only when multiple RTKs were targeted by RNAi or combination TKI74.  Thus, the 
integration of genomic and proteomic insights with molecular dissection of the signaling complex 
now provides a more accurate blueprint for the rational deployment of TKIs in GBM, lung and 
other solid tumors.   
While critical to translation, establishing the molecular basis of cancer-relevant action of 
a GEOI in specific tumor-biological context is perhaps the most difficult step in cancer 
genomics.  Compounding the challenges of lengthy and laborious functional - clinicopathological 
validation (Figure 4) is the biological phenomenon of false negatives.  Such false negatives can 
arise in many ways, including when (i) cancer-related biological activities of a genetic element 
are not captured by standard cell-based cancer assays (e.g. interaction with the host stroma); 
(ii) genetic element plays relevant role but only under specific cellular or genetic context not 
recreated in the validation assay; or (iii) a genetic element contributes partially to the overall 
activity conferred by a genomic event, thus single GEOI activity is negligible in the absence of 
these cooperating partner(s).   Therefore, validation must not rely on a single assay by a single 
manipulation.  Gain-of-function and loss-of-function manipulations for multiple tumor-
phenotypes using multiple cell lines should be performed to search for the context in which 
biological activity can be revealed.  Here, one can benefit from other tumor biological knowledge 
of the disease or gene family or pathways, including insights from triangulation data that 
nominate the specific GEOI.  For example, if a GEOI identified by integrative genomic analyses 
is further prioritized on basis of its known role in neural-stem-cell (NSC) homeostasis, one will 
specifically assess how its manipulation impacts on NSC renewal/maintenance/differentiation in 
addition to the more generic assays of anchorage independence or proliferation (Figure 4).  
Similarly, if a GEOI is identified in a subset of tumors with a particular genotype (e.g. with 
activated RAS vs EGFR mutation), one needs to assay its biological importance under the 
appropriate context.  This has been demonstrated in two recent studies46,47.  Kim et al, showed 
that NEDD9 had gain-of-function pro-invasion activities only in cells with concomitant BRAF or 
RAS activation, an experimental design informed by the characteristics of the metastatic 
escapers harboring NEDD9 amplification46,47.  Zender et al, demonstrated cIAP1 and Yap 
exhibited oncogenic activities in p53+/- hepatoblasts with Myc activation, but not ones with Akt 
or RAS activation, consistent with the presence of 9qA1 amplicon (targeting cIAP1 and Yap) in 
that specific mouse model of HCC46,47.    In the Zender et al study, not one, but both cIAP1 and 
Yap were shown to be cooperative targets of 9qA1 amplification, highlighting yet-another level 
of complexity that contributes to biological false negatives.  Here, functional genomics can be an 
efficient path forward.  Not only does such approach allow increased throughput in assaying 
large number of GEOIs for tumor biological activities, genetic screens with low-complexity 
libraries representing GEOIs resident within a particular genomic event (especially ones that are 
large and gene-rich) will enable identification of cooperating contributors that together confer the 
biological advantage sought by the cancer cells.  This approach will likely be important for 
sorting out which of the less impressive “hills and valleys” are biologically important.  
Similarly challenging is the issue of biological false positives.  For instance, RNAi-
mediated loss-of-function assay is a powerful mean to determine whether expression of a GEOI 
is required in a cell for a specific turmorigenic phenotype (e.g. survival, anchorage 
independence or invasion etc).  However, given the innumerable genetic and epigenetic 
alterations present in established tumor cells (and consequent altered signaling between 
pathways and networks), it is possible that the phenotype observed may be true-true-unrelated.  
Here, complementary gain-of-function activity can help to increase the weight of evidence in 
support of a particular GEOI being a true driver or contributor to cancer.  Additionally, type of 
functional activity also conveys different level of confidence; anchorage independent growth in 
soft agar is a more stringent assay than enhanced proliferation in fully supplemented cultured 
media with 10% serum.  Biological false positive can also emerge as a direct consequence of 
the artificial nature of our assays.  Consider the possibility that overexpression of a GEOI may 
confer a strong anchorage independent phenotype, but such may be the result of its 
supraphysiological level of expression in vitro;  conversely, knockdown of a GEOI may lead to 
cell death for its expression is required for survival of all cells, not just cancerous ones.  Here, 
clinicopathological validation utilizing tissue microarrays can provide added support for cancer-
relevance by demonstrating prevalence of dysregulation on DNA (by FISH) and protein (by IHC 
or IF) levels in independent large cohorts of specific tumor types and of broad tumor spectrum.  
This can be particularly informative if such TMA cohorts are annotated with clinical outcome as 
such survey will not only add to the weight of evidence, but also provide invaluable clues and 
insights into possible clinical context for therapeutic development.   In the end, it is the 
cumulative weight of evidence based on strength of specific functional activities, magnitude of 
clinicopathological data as well as significance of mechanistic clues that ultimately gives one the 
confidence of assigning a GEOI as a cancer-relevant “driver” or “contributor” rather than a mere 
passenger.   
  
Conclusion 
Cancer is the phenotypic endpoint of numerous epi/genomic alterations accumulated 
within the cancer cells and interactions of such alterations with the stromal components in a 
unique host microenvironment.  Some of the major challenges in translation of cancer genomics 
stem from the fact that many cancer-associated DNA changes represent genomic noise and 
there is incomplete understanding of the biological functions of many of the genetic elements in 
recurrent genomic alterations.  Compounding these is the unfortunate reality that cancer is a 
highly complex, nimble and versatile disease.  We have argued here that making sense of this 
complexity can be greatly facilitated by triangulation and integration with genomic and biological 
insights from model systems and clinical knowledge of the disease, and that translation can be 
accelerated by rigorous biological validation and mechanistic exploration in preclinical setting to 
better define the clinical context(s) in which a specific genetic element (or its linked 
pathway/network components) represents an effective therapeutic point of intervention.  At the 
same time, we need to be mindful that our current knowledge of what makes a strong driver, a 
cooperating contributor or, for that matter, a genomic passenger is limited at best and possibly 
wrong.  Therefore, this must be an iterative learning process where results of downstream 
biological validation and mechanistic studies, even clinical experiences when inhibitors or 
biomarkers are developed and deployed, can and must inform the integrative analyses and the 
validation approaches.  This effort will be facilitated by development or assembly of model 
systems that are characterized to the same degree as primary tumors that can be used to 
quickly test hypotheses suggested by the tumor “omic” analyses.  In other words, efficient 
translation of cancer genomics must go beyond statistical analyses of large genomic datasets 
and will require the amalgamation of expertise and insights from cancer biology, cancer 
genetics, cancer modeling and system biology as well as clinical experiences.  While each of 
these components may be pursued in an individual laboratory or research program, effective 
integration will enable timely exchange and bring synergy not possible otherwise.  Therefore, in 
parallel of multiple national and international large-scale cancer genome projects aimed at 
systematic and comprehensive characterization of the human oncogenome, it is also important 
to establish cancer genome translation centers or cooperatives where such diverse expertise 
can be assembled and efforts coordinated to mine the rich genomic datasets, generate 
hypotheses for validation, elucidate mechanisms and rationally design clinical development plan 
for biomarkers and therapeutics. 
 
 
 
Textbox:  Translating the cancer genome 
Comprehensive analyses of genome copy number, transcription, epigenomic 
modification and DNA sequence in cancers are now underway worldwide.  A central challenge 
in analyzing complex datasets emerging from these efforts is to devise strategies to efficiently 
prioritize (epi)genomic aberrations for assessment of biological importance and translational 
potential.  Traditionally, such prioritization is based on recurrence of the aberrations, 
associations with clinical endpoints such as histopathology and outcome, as well as biological 
activities.  A rapidly evolving suite of technological solutions now enable analysis of the 
oncogenomic landscape with remarkable resolution and accuracy.  
Copy number aberrations.  Comparative genomic hybridization (CGH) allows changes 
in genome copy number to be mapped onto a representation of the normal genome thereby 
allowing ready identification of the genes involved in the aberrations.  Modern CGH analysis 
platforms map these changes onto DNA sequences arranged in microarrays and allow 
quantitative assessment of changes in genome copy number in cancer genomes - including 
individual alleles in some platforms – with subgene resolution. Even at this resolution, some 
aberrations may be missed, especially with platforms that are gene oriented given the growing 
appreciation of the roles of regulatory, non-coring RNA transcripts in cancer pathogenesis.  Next 
generation technologies that efficiently sequence small genome fragments randomly collected 
from tumor genomes will complement microarray based copy number analysis strategies  by 
allowing sequencing of sufficiently large numbers of DNA fragments that copy number along the 
genome can be assessed simply by summing up the number of DNA sequence elements in 
genome resolution elements distributed along the genome.  The resolution of this approached 
can be made arbitrarily high by sequencing to increasing depth. 
Structure aberrations. Structural changes may involve segmental deletions or 
insertions, translocations or complex rearrangements (e.g. those occurring during gene 
amplification or copy number change).  These may be discovered using sequence based 
strategies. (a) End sequence profiling (ESP) is an adaptation of whole genome shotgun 
sequencing that allows detection of structural aberrations23 in which DNA from a tumor is cloned 
into a large insert vector and the ends of the resulting clones are sequenced and mapped onto 
the normal human DNA sequence.  Paired ends that map farther apart than the maximum size 
tolerated by the cloning vector indicate the presence of a structural aberration. This approach 
has the advantage clones containing aberrant DNA sequence fusion can be sequenced to 
identify the exact DNA sequence at the breakpoint.  (b) Paired end sequencing combines the 
rescue and capture of paired ends of short DNA fragments with high throughput sequencing  
and a computational approach to map DNA reads onto a reference genome to reveal structural 
variants 75.  
DNA sequence abnormalities.  Recent large scale DNA sequence analysis efforts 
have identified several hundred candidate cancer genes that may play function roles in various 
human cancers39,40.   Some occur at relatively high frequency but most are present in only a few 
percent of tumors.  Results from the extensive sequencing and mutation validation efforts now 
underway will be necessary to establish prevalence and clinicopathological associations for 
these GEOIs.  Both established and next generation sequencing technologies will be brought to 
bear on this issue.  (a) Sequencing by bybridization (SBH) 76 is an array based strategy in which 
mutations are detected based on intensity of hybridization to arrays comprised of comprised of 
short oligonucleotide probes that are designed to be perfectly complementary to the reference 
sequence plus oligonucleotide probes that differ by one base at each “substitution position” in 
the genome to be tested for mutation. This approach is well suited to resequencing.  (b) Dideoxy 
sequencing 77 is the current standard mutation detection methodology. Dideoxy sequencing 
typically is applied to products resulting from PCR amplification using primers that flank regions 
of interest.  Sequence “reads” typically are about 750 bp.  Most implementations of mutation 
detection using dideoxy sequencing will miss mutations that are present in less than about 20% 
of the cells in the PCR amplified population. Mutations discovered so far are summarized at 
http://www.sanger.ac.uk/genetics/CGP/cosmic/. (c) Shotgun sequencing proceeds by 
fragmenting a target genome into numerous small segments that are sequenced using dideoxy 
sequencing. Most regions of the genome will be sequenced several times and computer 
programs assemble overlapping sequences into a contiguous sequence.  (d) Single Molecule 
Sequencing Methods allow genome wide DNA sequencing starting from single molecules rather 
than a population of molecules 78,79.   Current read lengths range from ~30 to 300 bp and the 
number of reads per analysis ranges from 300,000 to 30,000,000.  These technologies facilitate 
detection of rare mutations.  Recent affinity enrichment techniques allow subsets of the genome 
to be enriched prior to sequencing (e.g. all known exons) thereby decreasing the cost of 
targeted sequencing 40,80. 
Epigenome analysis.  It is clear that epigenomic modifications are major contributors to 
tumorigenesis and progression – especially during early stages of development.  Several 
techniques for genome wide assessment of DNA methylation and chromatic structure are now 
established or emerging that will facilitate further elucidation of the oncogenomic roles 
epigenomic aberrations play. (a) Restriction Length Genomic Scanning (RLGS) 81 using 
methylation sensitive enzymes was the first method developed as a genome-wide screen for 
CpG island methylation.  This double-restriction-digest, gel separation technique allows analysis 
of methylation in up to 4000 loci 82,83. (b) Microarray array epigenome analysis methods 84 
proceed via hybridization of tumor and reference DNA samples arrays comprised of 
oligonucleotides comprised of CpG island sequences after digestion with methylation sensitive 
restriction enzymes that cut preferentially in CpG islands. Comparison of signal intensities 
derived from the tumor and reference samples provides a profile of sequences that are 
methylated in the tumor but not the references (or vise versa).   (c) Reduced representation 
bisulfite sequencing (RBBS) 85 is a large-scale genome-wide shotgun sequencing approach in 
which  tumor  and reference DNA samples are treated with bisulfate to convert cytosine to uracil 
while leaving 5-methylcytosine unconverted, digested with a methylation specific enzyme and 
sequenced.  Comparison of CpG sequences in the tumor and reference genomes could then 
reveal bisulfite induced changes.  This method is well suited to next generation single molecule 
sequencing strategies.  (d) methylation-specific Digital Karyotyping (MSDK) methodology 86 is a 
modification of digital karyotyping technique for DNA copy number profiling 87 where sequencing 
is performed to count accurately tag numbers for comparison between samples, thereby 
permitting quantitative measurement of methylation events. (e) Chromatin immunoprecipitation 
plus microarray analysis (ChIP on chip)88 employs immunoprecipitation to enrich DNA 
sequences associated with chromatin modifications such as histone acetylation and histone H3 
methylation for which antibodies are available. Immunoprecipitated DNA sequences are 
analyzed using microarray technologies or single molecule sequencing strategies. 
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Figure Legend 
 
Figure 1. Illustration of various types of genomic and epigenomic aberrations in cancers and 
type of genomic data that report on such changes.  These alterations presumably will lead to 
altered expression of resident genetic element of interest (GEOI), including coding mRNA and 
non-coding microRNA.  GEOI expression changes can manifest as increased or decreased 
level of expression or shift in pattern of spliced variant expression or appearance of aberrant 
transcripts that are cancer specific, such as ones derived from a fusion gene.   
 
Figure 2.  Integrative genomic analyses of human cancers of different cell lineages can be 
triangulated with genomic and biological data from tumors and genetics from model systems 
and from forward genetic screens in human cell systems.  Additionally, association with clinical 
parameters can prioritize GEOIs.  GEOIs identified from such integrative analyses will require 
biological and clinicopathological validation, a laborious process that can be greatly accelerated 
by deployment of functional genetic screens.  Exploration of mechanistic basis for a GEOI’s 
cancer-relevant activities can provide hints to their uses in the clinics.  Results from these 
downstream activities will feed back to inform and refine analyses and derive improved 
validation platforms. 
 
Figure 3.  Illustrative signaling pathway, highlighted with known examples of bona fide cancer 
genes that are subjected to deregulation by multiple genomic mechanisms. 
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